PTPN11 - Wiki-Pi

Search Results for: PTPN11

Can't find the interaction you're looking for? Try the advanced search

174 interactions involving PTPN11 - protein tyrosine phosphatase non-receptor type 11 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases

Novel	Symbol	Description	Pathways Hide	Drugs Hide	Diseases Hide
Novel	BRAP	BRCA1 associated protein	RAF activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants
Novel	HIP1R	huntingtin interacting protein 1 related	Golgi Associated Vesicle Biogenesis Clathrin-mediated endocytosis
Novel	MVK	mevalonate kinase	Cholesterol biosynthesis Activation of gene expression by SREBF (SREBP)	Farnesyl thiopyrophosphate	Mevalonate kinase deficiency; Hyperimmunoglobulinemia D; Mevalonic aciduria
Novel	NCOR2	nuclear receptor corepressor 2	PPARA activates gene expression NOTCH1 Intracellular Domain Regulates Transcription Downregulation of SMAD2/3:SMAD4 transcriptional activity Downregulation of SMAD2/3:SMAD4 transcriptional activity Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants HDACs deacetylate histones Notch-HLH transcription pathway Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway SUMOylation of transcription cofactors Regulation of lipid metabolism by PPARalpha Loss of MECP2 binding ability to the NCoR/SMRT complex Regulation of MECP2 expression and activity NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux HCMV Early Events NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis Cytoprotection by HMOX1 MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
Novel	NRG3	neuregulin 3	Signaling by ERBB2 Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PI3K events in ERBB4 signaling SHC1 events in ERBB4 signaling Nuclear signaling by ERBB4 PIP3 activates AKT signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 TMD/JMD mutants
Novel	P2RX7	purinergic receptor P2X 7	Elevation of cytosolic Ca2+ levels Platelet homeostasis The NLRP3 inflammasome The NLRP3 inflammasome Purinergic signaling in leishmaniasis infection Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	Promethazine
Novel	RCOR3	REST corepressor 3
	AATK	apoptosis associated tyrosine kinase
	ACTN4	actinin alpha 4	Platelet degranulation Nephrin family interactions		Nephrotic syndrome and focal segmental glomerulosclerosis
	AKT1	AKT serine/threonine kinase 1	Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation MTOR signalling AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network eNOS activation AKT-mediated inactivation of FOXO1A Integrin signaling Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity Extra-nuclear estrogen signaling Negative regulation of NOTCH4 signaling FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Mitochondrial unfolded protein response (UPRmt) High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	ATP Arsenic trioxide Genistein Inositol 1,3,4,5-Tetrakisphosphate Resveratrol Archexin Enzastaurin Perifosine N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
	ALK	ALK receptor tyrosine kinase	Signaling by ALK Signaling by ALK ALK mutants bind TKIs ASP-3026-resistant ALK mutants NVP-TAE684-resistant ALK mutants alectinib-resistant ALK mutants brigatinib-resistant ALK mutants ceritinib-resistant ALK mutants crizotinib-resistant ALK mutants lorlatinib-resistant ALK mutants Signaling by ALK fusions and activated point mutants MDK and PTN in ALK signaling MDK and PTN in ALK signaling	ATP Crizotinib Ceritinib Alectinib Fostamatinib Lorlatinib Gilteritinib Brigatinib	Non-small cell lung cancer
	AR	androgen receptor	HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 Ub-specific processing proteases RUNX2 regulates osteoblast differentiation RUNX2 regulates osteoblast differentiation	Diethylstilbestrol Levonorgestrel Progesterone Spironolactone Flutamide Oxandrolone Fluphenazine Testosterone Mitotane Estrone Nilutamide Tamoxifen Norethisterone Drostanolone Norgestimate Nandrolone phenpropionate Ketoconazole Acetophenazine Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone propionate Oxybenzone 1-Testosterone Boldenone Calusterone Periciazine Prasterone Flufenamic acid Stanolone (R)-Bicalutamide Metribolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone acetate LGD2941 Dimethylcurcumin Oxymetholone Methyltestosterone Norelgestromin Stanozolol Tetrahydrogestrinone (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide BMS-564929 S-23 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide Andarine (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile LGD-2226 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Triclosan Nandrolone decanoate Ulipristal Enzalutamide Eugenol Dienogest Norethynodrel Norgestrel Homosalate Enzacamene Luprostiol Mibolerone Phenothiazine Gestrinone Apalutamide Clascoterone Darolutamide Esculin Ligandrol Testosterone cypionate Testosterone enanthate Testosterone undecanoate Stanolone acetate Segesterone acetate Boldenone undecylenate Echinacoside Ketodarolutamide	Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism Prostate cancer 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
	ARHGAP1	Rho GTPase activating protein 1	RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOQ GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RAC3 GTPase cycle RHOF GTPase cycle RND2 GTPase cycle
	AXL	AXL receptor tyrosine kinase	VEGFA-VEGFR2 Pathway	Fostamatinib Gilteritinib
	BCR	BCR activator of RhoGEF and GTPase	Signaling by cytosolic FGFR1 fusion mutants Signaling by FGFR1 in disease RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RAC3 GTPase cycle	Imatinib Dasatinib Bosutinib Ponatinib	Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Chronic myeloid leukemia (CML)
	BDKRB2	bradykinin receptor B2	Peptide ligand-binding receptors G alpha (q) signalling events G alpha (i) signalling events	Anatibant Icatibant Labradimil
	BEX1	brain expressed X-linked 1
	BEX2	brain expressed X-linked 2
	BLZF1	basic leucine zipper nuclear factor 1	Golgi Cisternae Pericentriolar Stack Reorganization
	BTLA	B and T lymphocyte associated	Co-inhibition by BTLA Co-inhibition by BTLA

Page 1 out of 9 pages